[1] Ozülker T, Kücüköz Uzun A, Ozülker F, et al.  Comparison of 18FFDG-PET/CT with 99mTc-MDP bone scintigraphy for the detection of bone metastases in cancer patients[J]. Nucl Med Commun, 2010, 31(6): 597-603.   doi: 10.1097/MNM.0b013e328338e909
[2]

Liu T, Cheng T, Xu W. A meta-analysis of 18FDG-PET, MRI and bone scintigraphy for diagnosis of bone metastases in patients with breast cancer [J/OL]. Skeletal Radiol, 2010[2010-05-22]. http://www.springerlink.com/content/b400915kn767k582/fulltext.pdf.
[3] Messiou C, Cook G, deSouza NM.  Imaging metastatic bone disease from carcinoma of the prostate[J]. Br J Cancer, 2009, 101(8): 1225-1232.   doi: 10.1038/sj.bjc.6605334
[4] Bury T, Barreto A, Daenen F, et al.  Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer[J]. Eur J Nucl Med, 1998, 25(9): 1244-1247.   doi: 10.1007/s002590050291
[5] Cheran SK, Herndon JE 2nd, Patz EF Jr.  Comparison of wholebody FDG-PET to bone scan for detection of bone metastases in patients with a new diagnosis of lung cancer[J]. Lung Cancer, 2004, 44(3): 317-325.   doi: 10.1016/j.lungcan.2003.11.008
[6] Stefan K, Andreas K, Buck Felix M, et al.  Detection of bone metastases in patients with lung cancer 99mTc-MDP planar bone scintigraphy, 18F-fluoride PET or 18F-FDG PET/CT[J]. Eur J Nucl Med Mol Imaging, 2009, 36(11): 1807-1812.   doi: 10.1007/s00259-009-1181-2
[7] Marom EM, McAdams HP, Erasmus J, et al.  Staging non-small cell lung cancer with whole-body PET[J]. Radiology, 1999, 212(3): 803-809.   doi: 10.1148/radiology.212.3.r99se21803
[8] Buck AK, Herrmann K, Stargardt T, et al.  Economic evaluation of PET and PET/CT in Oncology: evidence and methodologic approaches[J]. J Nucl Med Technol, 2010, 38(1): 6-17.   doi: 10.2967/jnmt.108.059584
[9] Cook GJ.  Skeletal metastases: what is the future role for nuclear medicine?[J]. Eur J Nucl Med Mol Imaging, 2009, 36(11): 1807-1812.   doi: 10.1007/s00259-009-1181-2
[10] Ito S, Kato K, Ikeda M, et al.  Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer[J]. J Nucl Med, 2007, 48(6): 889-895.   doi: 10.2967/jnumed.106.039479
[11] Hamaoka T, Madewell JE, Podoloff DA, et al.  Bone imaginging metastatic breast cancer[J]. J Clin Oncol, 2004, 22(14): 2942-2953.   doi: 10.1200/JCO.2004.08.181
[12] Goya M, Ishii G, Miyamoto S, et al.  Prostate-specific antigen induces apoptosis of osteoclast precursors: potential role in osteoblastic bone metastases of prostate cancer[J]. Prostate, 2006, 66(15): 1573-1584.   doi: 10.1002/pros.20375
[13] Mundy GR.  Metastasis to bone: causes, consequences and therapeutic opportunities[J]. Nat Rev Cancer, 2002, 2(8): 584-593.   doi: 10.1038/nrc867
[14] Uematsu T, Yuen S, Yukisawa S, et al.  Comparison of FDG PET and SPECT for detection of bone metastases in breast cancer[J]. AJR Am J Roentgenol, 2005, 184(4): 1266-1273.   doi: 10.2214/ajr.184.4.01841266
[15] Ohta M, Tokuda Y, Suzuki Y, et al.  Whole body PET for the evaluation of bony metastasesin patients with breast cancer: comparison with 99mTc-MDP bone scintigraphy[J]. Nucl Med Commun, 2001, 22(8): 875-879.   doi: 10.1097/00006231-200108000-00005
[16] Schirrmeister H, Guhlmann A, Elsner K, et al.  Sensitivity in detecting osseous lesions depends on anatomic localization: planar bone scintigraphy versus 18F PET[J]. J Nucl Med, 1999, 40(10): 1623-1629.
[17] Metser U, Lerman H, Blank A, et al.  Malignant involvement of the spine: assessment by 18F-FDG PET/CT[J]. J Nucl Med, 2004, 45(2): 279-284.
[18] Nakai T, Okuyama C, Kubota T, et al.  Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer[J]. Eur J Nucl Med Mol Imaging, 2005, 32(11): 1253-1258.   doi: 10.1007/s00259-005-1842-8